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Herd effectBackground: Since the introduction of pneumococcal conjugate vaccines, vaccine type pneumococcal car-
riage and disease has decreased world-wide. The aim was to monitor changes in the nasopharyngeal car-
riage of pneumococci, the distribution of serotypes and antimicrobial resistance in children before and
after initiation of the 10-valent pneumococcal vaccination in 2011, in a previously unvaccinated popula-
tion.
Methods: Repeated cross-sectional study at 15 day-care centres in greater Reykjavik area.
Nasopharyngeal swabs were collected yearly in March from 2009 to 2015. The swabs were selectively
cultured for pneumococci, which were serotyped using latex agglutination and/or PCR and antimicrobial
susceptibility determined. Two independent studies were conducted.
In study 1, on total impact, isolates from children aged <4 years were included. The vaccine-eligible-
cohort (birth-years: 2011–2013, sampled in 2013–2015) was compared with children at the same age
born in 2005–2010 and sampled in 2009–2012. In study 2 on herd effect, isolates from older non-
vaccine-eligible children (3.5–6.3 years) were compared for the periods before and after the vaccination
(2009–2011 vs 2013–2015. Vaccine impact was determined using 1-odds-ratio.
Results: Following vaccination, the vaccine impact on vaccine type acquisition was 94% (95% CI: 91–96%)
in study 1 and 56% (95% CI: 44–65%) in study 2. The impact on serotype 6 A was 33% (95% CI:9%; 59%) in
study 1 and 42% (95% CI: 10–63%) in study 2 with minimal effect on 19A. The non-vaccine serotypes/
groups 6C, 11, 15 and 23B were the most common serotypes/groups after vaccination. Isolates
from the vaccine-eligible-cohort had lower penicillin MICs, less resistance to erythromycin and co-
trimoxazole and less multi resistance than isolates from the control-group.
Conclusions: The efficacy of the vaccination on vaccine serotypes was high, and a milder effect on
vaccine-associated-serotype 6A was observed for the vaccine-eligible-cohort. There was a significant
herd effect on vaccine types in older non-vaccine-eligible children. Overall antimicrobial non-
susceptibility was reduced.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Streptococcus pneumoniae, is an important pathogen in respira-
tory tract and invasive pneumococcal infections (IPD), especially in
children [1,2]. Acute otitis media (AOM) is among the most com-
mon reasons for health care visits and the most common reasonfor antibiotic prescriptions [3] in young children, contributing to
antimicrobial resistance [4]. Major risk factors for pneumococcal
carriage and antibiotic resistance include young age, crowding,
recent upper respiratory tract infection, day-care centre (DCC)
attendance, larger family size, passive smoking and low socioeco-
nomic status [5–9]. In addition, recent or current antimicrobial
usage temporarily reduces the risk of carriage [7,8]. Nasopharyn-
geal (NP) carriage of pneumococci is a prerequisite for pneumococ-
cal infections [10]. Therefore, it is important to monitor the
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ynx of children.
Penicillin non-susceptible pneumococci (PNSP) are of world-
wide concern and the main risk factors for PNSP infections are
young age and recent antibiotic usage [4,5,7,8]. In recent years, ser-
otype 19F has been the most common PNSP and multi-resistant
serotype in Iceland [11].
Vaccinations with pneumococcal conjugate vaccines (PCVs)
have resulted in a lower incidence of IPD [2,12–16], AOM
[2,12,17–19] and pneumonia [2,12,18,20], especially in children.
Decrease in nasopharyngeal carriage of vaccine types and replace-
ment by non-vaccine types after implementation of vaccination in
childhood vaccinations schedules has been widely reported both in
vaccinated children [2,9,12,19,21–26] and children not vaccinated
[2,27].
The 10-valent protein conjugated pneumococcal vaccine (PHiD-
CV) was added to the childhood vaccination schedule in Iceland in
2011 for all children born that year without catch-up (at 3, 5 and
12 months of age). This population had previously not been rou-
tinely vaccinated against pneumococci. In this investigation, we
report the results from two analyses (referred to as study 1 and
2). The aim of the first one was to compare pneumococcal carriage
rate, serotype distribution and prevalence of antibiotic resistant
pneumococci in the nasopharynx of healthy children attending
DCC before and after the initiation of the vaccination. The second
analysis evaluated the herd effect on unvaccinated children in DCC.2. Material and methods
The study is an ongoing, repeated cross-sectional study where
nasopharyngeal samples are collected annually (in March) from
children attending 15 DCCs in the Reykjavik capital area, from
2009 to 2015. The DCCs were selected so they would be represen-
tative both geographically and socially for the Reykjavik capital
area. The same 15 DCCs participated during the whole study period
with only two exceptions, where they were changed for neigh-
bouring DCCs due to scheduling difficulties.
The children attending the DCCs participating in this study are
aged from 1.1 years (earliest time of entering DCC) to 6.3 years of
age (when leaving DCC and starting primary school). All children
attending the DCCs were invited to participate in this study. Signed
informed consent forms were obtained and parents were asked to
fill in questionnaires including questions on current and previous
30-day usage of antimicrobials and whether the child had been
diagnosed with acute otitis media, sinusitis or pneumonia by a
physician in the previous six months.
Single nasopharyngeal sample was obtained (COPAN transport
medium swabs, Copan, Italy) from each child attending the DCCs
on the day of sampling for which informed consent had been
obtained. Children could participate more than once if they were
still attending the DCC in the later years, at the day of sampling.
Although many children participated more than once in the study,
these events were considered independent in the main analysis. In
an analysis of carriage of 19F, individual data was examined to
search for repeated carriage of 19F. The swabs were inoculated
within six hours of sampling and selectively cultured for pneumo-
cocci on blood agar containing 5 mg/mL gentamicin. The blood agar
plates were incubated anaerobically at 35 C for 18–20 h using
anaerobic jars with gaspak envelopes to create a reduction in O2
and an increase in CO2 concentrations [28]. Pneumococci were
identified by morphology and susceptibility to optochin. Normally,
when all colonies appeared identical two to four colonies were
selected for antimicrobial susceptibility testing and serotyping. If
there were colonies with different morphology [28], additionaltwo to four colonies were selected from each type for susceptibility
testing as well as serotyping.
All pneumococcal isolates were tested for antimicrobial suscep-
tibilities using disc diffusion and the EUCAST methods and criteria
(www.eucast.org; to erythromycin, clindamycin, tetracycline and
trimethoprim/sulfamethoxazole). The isolates were screened for
penicillin non-susceptibility with oxacillin discs and penicillin
MIC measured for all oxacillin resistant isolates using the E-test
(BioMérieux, France). Isolates defined as PNSP were divided into
low MIC (0.094–0.5) and high MIC (>0.5) groups. Resistant and
intermediate resistant isolates were termed non-susceptible.
Multi-resistance was defined as non-susceptibility to at least three
different antimicrobial classes.
Serotyping was done as previously described [29] using pneu-
mococcal Latex antisera [30] (Statens Serum Institute, Denmark)
[28]. The same senior biomedical scientist did all the agglutina-
tions. When the latex agglutination test did not detect a specific
serotype, mono and multiplex PCR was used. The vaccine serotypes
(VT) were defined as serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and
23F. The Vaccine associated serotypes (VaT) were defined as 6A
and 19A. Non-vaccine serotypes (NVT) are those not belonging to
VT or VaT.
Information on pneumococcal vaccinations was acquired from
The National Vaccination Registry, and the percentage of children
from each birth-cohort receiving at least two PCV doses before
the age of two, were the following: For; 2003–2007: <1%, 2008:
2.4%, 2009: 7.4%, 2010: 19.2%, 2011: 97.7%, 2012: 98.4%, 2013:
98.7%.
2.1. Statistics
Statistics were done using the statistical software R version
3.3.2. Differences between characteristics of the children, overall
carriage prevalence of pneumococci, antimicrobial resistant pneu-
mococci and answers to questionnaires between study groups
were tested using two-sided Fisher’s exact test and z-test for cate-
gorical outcomes and t-test for continuous outcomes, using
a = 0.05 as significance level. Odds ratios and 95% confidence inter-
vals were calculated for the risk of carrying individual and pooled
serotypes in the vaccine and non-vaccine groups. The estimation of
vaccine impact on acquisition (VEacq) was determined by 1 – OR
as elucidated by Rinta-Kokko et al. [31]. Large sample theory was
used to construct approximate confidence intervals for VEacq
and a hypothesis test for the difference between two VEacq coeffi-
cients. When testing the null hypothesis of the VEacq difference
being equal to zero the distribution of the test statistic is approxi-
mated with a standard normal distribution. For serotypes with
zero observations in either of the groups a conservative one-
sided 95% confidence interval for vaccine impact was found by
replacing the observed zero with one. As some children carried
two serotypes the denominator for these analyses were number
of children in that group + number of children with dual carriage
in that group.
Two independent studies were done (Table 1).
Study 1. For the estimation of the total impact of the vaccina-
tion on children eligible for the vaccination, the vaccine eligible
cohorts (VEC, children born 2011 and later, sampled in 2013–
2015) were compared to the control group (CG, children born
2010 and earlier, sampled in 2009–2012). To attain comparable
age distribution, only children <4 years of age were included. To
minimize the potential bias caused by the herd effect, CG chil-
dren sampled in 2013 and later were not included.
Study 2. For the estimation of the herd effect on children not eli-
gible for the vaccination, children born 2010 and earlier were



















CG <4 years 2005–2010 2009–2012 2.9 2.9 (1.2–4.0) 853
VEC <4 years 2011–2013 2013–2015 2.8 2.8 (1.1–4.0) 371
Study 2: herd effect PreVac 3.5–6.3 years 2003–2007 2009–2011 5.0 5.0 (3.6–6.3) 847
PostVac 3.5–6.3 years 2007–2010 2013–2015 5.0 5.0 (3.6–6.2) 949
Two independent studies were conducted.
In Study 1 (Total impact), only children less than 4 years of age were included. Children born before the vaccine initiation (2010 and earlier, Control Group, CG), sampled in
2009–2012 were compared to children born after the vaccine initiation (2011 and later, Vaccine Eligible Cohort, VEC).
In Study 2 (Herd effect), only children between the ages 3.5 years and 6.3 years, born before the vaccination (birth-cohort 2010 and earlier) were included. Children sampled
in 2009–2012 were compared to those sampled in 2013–2015.
5244 S. Sigurdsson et al. / Vaccine 35 (2017) 5242–5248(sampled 2013–2015, PostVac period) the vaccination. To attain
comparable age distribution only children >3.5 and <6.5 years
of age were included. Isolates sampled in 2012 were excluded
as they belonged to the transition year. Sixteen children, born
in 2007 were sampled both in 2011 and 2013, were excluded
from the analysis.
In analysis of antibiotic non-susceptibility, non-typeable pneu-
mococci were excluded, as they are not considered an important
cause of disease in immunocompetent hosts.
The study was approved by The National Bioethics Committee
(VSNb2013010015/03.07), The National Data Protection Authority
(2013010100VEL/–), The University Hospital medical director and
the appropriate directorates of the DCC’s. The study is a part of a
larger study on vaccinations in Iceland (The VIce study).3. Results
3.1. Study on the impact on the vaccine eligible cohorts
The number of children was 853 in the CG and 371 in the VEC.
The average age in the CG was 2.89 and 2.80 in the VEC (p < 0.05),
the median age and ranges were 2.90 (1.15–4.00) and 2.80 (1.10–
4.00) (Table 1). Males were 51.4% and 53.7% (p = 0.45) of children
in CG and VEC respectively. Dual carriage was 7.5% in the CG and
4.3% in the VEC (p = 0.051). No difference was found in overall car-
riage prevalence of pneumococcus (69.5% vs 70.1%, p = 0.84).
Parent-reported recent antibiotic use was lower in the VEC group
than in the CG (17.8% vs 23.2%, p < 0.05), with no difference in
parent-reported respiratory tract infections (RTIs) in the previous
6 months (43.8% vs 41.8%, for the CG and VEC respectively,
p = 0.54).
The vaccine impact for VT carriage was 94% (95% CI: 91–96%),
with reduction of individual serotypes ranging from 84% to 100%.
The combined impact against the VaT (6A and 19A) was 33%
(95% CI: 1–55%), with non-significant individual impact being
33% (95% CI: 9%; 59%) and 29% (95% CI: 31%; 61%) for 6A and
19A respectively (Tables 2 and 5). Serotype replacement was noted
with non-vaccine serotypes being more common in the VEC than
CG (53% vs 18%, respectively). Serogroup 15 was the most preva-
lent isolate in the VEC, 9.6% compared to 3.9% in the CG. The great-
est difference was noted for Serotype 23B (0.8% vs 7.8% for CG and
VEC, respectively) (Table 2).
The prevalence of PNSP isolates in CG and VEC was similar.
When comparing these groups after stratifying the MIC into low
vs high MIC a significant difference was found between the CG
and VEC, where the isolates from the VEC were mainly in the
low MIC range and the CG mainly in the high MIC range (Table 3).
The prevalence of co-trimoxazole and erythromycin resistance
was higher in the CG than VEC, 22.1% and 13.1% vs 12.1%
(p < 0.001) and 9.0% (p < 0.05) respectively. The prevalence of clin-damycin, tetracycline, erythromycin and penicillin non-susceptible
strains did not differ between the two cohorts. Resistance to 3
antibiotic classes were more common in the CG than the VEC
9.4% vs 1.6% respectively (p = 0.003). Isolates that showed non-
susceptibility to all antibiotics tested (penicillin, erythromycin,
co-trimoxazole, tetracycline and clindamycin) were also more
common in the CG, 4.4% vs 0.3% (p < 0.001) respectively (Table 3).
Serotypes/groups non-susceptible to 3 antibiotic classes
belonged to serotypes 19F (n = 73), 6B (n = 6), 14 (n = 2) and 6C
(n = 1) in the CG and 15 (n = 8), 19F (n = 5) and 6C (n = 3) in the
VEC. Isolates non-susceptible to all five antibiotics tested belonged
to serotypes 19F (n = 30), 6B (n = 6) and 14 (n = 2) in the CG and
19F (n = 1) in the VEC.
3.2. Study on the herd effect
There were 831 children in the pre-vaccination (PreVac) period
and 933 in the post vaccination (PostVac) period. The average age
in the PreVac period was 4.97 and 4.98 in the PostVac period
(p = 0.83) and median ages (with ranges) were 4.96 (3.59–6.33)
and 5.00 (3.59–6.22) respectively (Table 1). Males were 49.4%
and 51.2% of participants in PreVac and PostVac respectively. Dual
carriage was seen in 5.8% and 5.0% respectively (p = 0.56). No dif-
ference was found in overall carriage (62.6% vs 64.4%, p = 0.42 for
PreVac period and PostVac period, respectively).
For the PostVac the vaccine impact against acquisition of VT
was 56% (95% CI: 44–65%) and 33% (95% CI: 7–51%) for 6A and
19A. A significant VEacq was found for 6A and VTs 6B, 9V, 14,
18C and 23F. (Tables 4 and 5). Further analysis of the 19F carriage
prevalence showed stable prevalence over the study-period of
study 2 with 4.2%, 2.7%, 4.7%, 4.2%, 4.5% and 3.1% of isolates being
19F for the study years 2009, 2010, 2011, 2013, 2014 and 2015
respectively. Of the 39 isolates of serotype 19F identified in the
PostVac period, seven were sampled from children that carried
19F more than once, and up to 3 years in-a-row. Vaccine serotypes
1, 5 and 7F were not isolated. Serotype replacement was noted, but
no change in total NP carriage. Non-vaccine serotypes increased
from 24.5% of all isolates in the PreVac to 42.6% in the PostVac. Ser-
otypes 6C, 10, 21, 22, 23A, 23B, 35B and 35F/47F all differed signif-
icantly between the periods and were more common in the
PostVac period. Serotype 23B differed the most between the peri-
ods, 0% vs 4.5% in the PreVac and PostVac, respectively (Table 4).
The prevalence of PNSP was 5.0% in both study periods
(p > 0.99). The prevalence of erythromycin, clindamycin, tetracy-
cline, combined penicillin and erythromycin and multi resistance
did not differ significantly between the PreVac and PostVac periods
(6.2% vs 4.4%, p = 0.12, 3.6% vs 2.5%, p = 0.26, 5.2% vs 5.1%, p = 0.97,
4.2% vs 3.7%, p = 0.70 and 5.0% vs 3.3%, p = 0.09, respectively). The
prevalence of co-trimoxazole non-susceptibility was significantly
higher in the PreVac than in the PostVac (13.4% vs 8.3%, p < 0.001).
19F was the dominant serotype causing penicillin non-
susceptibility and multi-resistance in both periods, causing 66.7%
Table 2
PHiD-CV vaccine impact estimates by serotype, for vaccine eligible cohort compared to control cohort.
Serotype Number of CG isolates (%) Number of VEC isolates (%) VEacq (95% CI) p-value
VT VT total 322 (35.1) 12 (3.1) 0.94 (0.91; 0.96) <0.001
6B 77 (8.4) 2 (0.5) 0.94 (0.84; 0.98) <0.001
9V 3 (0.3) 0 (0) 1.00 (6.57; 1.00)k 0.26
14 57 (6.2) 0 (0) 1.00 (0.85; 1.00)k <0.001
18C 6 (0.7) 0 (0) 1.00 (2.04; 1.00)k 0.11
19F 84 (9.2) 6 (1.6) 0.84 (0.67; 0.93) <0.001
23F 95 (10.4) 4 (1) 0.91 (0.80; 0.96) <0.001
VAT VAT total 122 (13.3) 36 (9.3) 0.33 (0.01; 0.55) 0.04
6A 76 (8.3) 22 (5.7) 0.33 (0.09; 0.59) 0.1
19A 46 (5) 14 (3.6) 0.29 (0.31; 0.61) 0.27
NVT NVT total 169 (18.4) 207 (53.5) 4.09 (5.53; 2.97) <0.001
3 14 (1.5) 11 (2.8) 0.89 (3.14; 0.14) 0.11
6C 8 (0.9) 25 (6.5) 6.85 (14.6; 2.94) <0.001
10 0 (0) 8 (2.1) Not calculated
11 32 (3.5) 32 (8.3) 1.49 (3.07; 0.53) <0.001
15 36 (3.9) 37 (9.6) 1.59 (3.10; 0.63) <0.001
16F 9 (1) 2 (0.5) 0.48 (1.37; 0.88) 0.4
21 4 (0.4) 10 (2.6) 5.05 (15.9; 1.17) <0.001
22 2 (0.2) 5 (1.3) 4.99 (24.5; 0.41) 0.02
23A 19 (2.1) 18 (4.7) 1.31 (3.37; 0.22) 0.01
23B 7 (0.8) 30 (7.8) 9.92 (20.5; 4.56) <0.001
29/35B 5 (0.6) 9 (2.3) 3.34 (10.9; 0.58) 0.004
33 13 (1.4) 2 (0.5) 0.64 (0.51; 0.91) 0.16
35F/47F 0 (0) 10 (2.6) Not calculated
38 8 (0.9) 1 (0.3) 0.71 (1.09; 0.96) 0.22
Other 7 (0.8) 6 (1.6) 1.05 (5.00; 0.30) 0.19
NT 47 (5.1) 22 (5.7) 0.12 (0.88; 0.34) 0.68
NONE 261 (28.5) 111 (28.7) 0.01 (0.32; 0.22) 0.94
Total 917 (100) 387 (100)
Direct Vaccine impact on carriage prevalence. NVEC: Non-Vaccine eligible cohort, CG: Control group. Children in the CG sampled 2013 and later were excluded to prevent
possible bias caused by herd immunity. k Conservative one-sided 95% confidence interval for vaccine impact. The total number is higher than the number of children because
some children carried more than one serotype.
Table 3
Antibiotic non-susceptibility for vaccine eligible cohort compared to non-vaccine eligible cohort.
Non-susceptibility to: Number CG isolates (%) Number VEC isolates (%) OR (95% CI) p value
PNSP (all isolates) 97 (11.2%) 38 (10.4%) 0.92 (0.62; 1.38) 0.76
Penicillin (Low MIC) 9 (1.0%) 33 (9.0%) 9.48 (4.54; 20.3) <0.001
Penicillin (High MIC) 88 (10.1%) 5 (1.4%) 0.12 (0.047; 0.31) <0.001
Erythromycin 114 (13.1%) 33 (9.0%) 0.66 (0.44; 1.00) 0.05
Tetracycline 95 (10.9%) 31 (8.5%) 0.76 (0.48; 1.16) 0.22
Clindamycin 54 (6.2%) 26 (7.1%) 1.15 (0.70; 1.16) 0.61
Co-trimoxazole 192 (22.1%) 44 (12.1%) 0.48 (0.34; 0.69) <0.001
Penicillin and Erythromycin 82 (9.4%) 30 (8.2%) 0.86 (0.55; 1.33) 0.59
3 antibiotic classes 82 (9.4%) 16 (4.4%) 0.44 (0.25; 0.77) 0.003
All 5 tested antibiotics 38 (4.4%) 1 (0.27%) 0.06 (0.003; 0.37) <0.001
Number of isolates 869 365
Antimicrobial non-susceptibility in the CG and the VEC groups. For isolates with penicillin non-susceptibility non-typeable pneumococci were excluded. *PNSP penicillin non-
susceptible pneumococci. The denominator signifies the number of isolates (number of children sampled + number of children with dual carriage). CG: Control Group. VEC:
Vaccine Eligible Cohort.
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resistance in the PreVac period and 45.8% (22/48) of PNSP and
71.0% (22/31) of multi-resistance in the PostVac period.
The PreVac period reported 6.2% higher RTIs in the last
6 months (27.6 vs 21.4%, p = 0.003) and 3.3% more antibiotic usage
in the last 3 months than the PostVac (12.2 vs 8.9%, p = 0.02).
4. Discussion
The vaccine impact, determined as a reduction of VT pneumo-
cocci in the nasopharynx was very high and some VT serotypes
were not detected in the VEC and thus arguably eliminated from
the nasopharynx by the vaccination. This was also seen for unvac-
cinated children after the initiation of the vaccination – although
with lower impact, indicating an important herd effect. This is inline with other studies on the PCVs which have showed reduction
in VT pneumococci [9,15,19,21–24,26,32]. Interestingly, despite
strong direct effect on carriage of 19F, no obvious herd effect was
observed. As 19F is the most antibiotic resistant serotype in this
study its persistence in older, unvaccinated children is of concern.
Of the 40 children carrying 19F in the PostVac period, seven carried
the serotype, at one to three sampling-occasions. Persistent, con-
tinuous low level carriage of 19F has been described in older chil-
dren after initiation of PCV [33].Waning immunity in older
children [34] and longer duration of carriage may be important fac-
tors for this persistent or repeated carriage of 19F [35–37].
Carriage was similar as in earlier studies conducted in Iceland
[5,7] but higher than most other studies [9,21,22]. This high car-
riage can partly be due to the study design, as all isolates were pla-
ted within six hours and cultured on selective medium under
Table 4
Indirect PHiD-CV vaccine impact estimates by serotype for PreVac compared to PostVac.
Serotype PreVac period (%) PostVac period (%) VEacq (95% CI) p value
VT VT total 219 (24.91) 125 (12.76) 0.56 (0.44; 0.65) <0.001
4 2 (0.23) 0 (0) 1.00 (3.65; 1.00)k 0.14
6B 51 (5.8) 27 (2.76) 0.54 (0.27; 0.71) 0.001
9V 13 (1.48) 0 (0) 1.00 (0.68; 1.00)k <0.001
14 26 (2.96) 14 (1.43) 0.53 (0.10; 0.75) 0.02
18C 28 (3.19) 10 (1.02) 0.69 (0.38; 0.84) <0.001
19F 34 (3.87) 39 (3.98) 0.03 (0.65; 0.36) 0.90
23F 65 (7.39) 35 (3.57) 0.54 (0.30; 0.69) <0.001
VAT VaT total 95 (10.81) 74 (7.55) 0.33 (0.07; 0.51) 0.01
6A 50 (5.69) 32 (3.26) 0.44 (0.12; 0.64) 0.01
19A 45 (5.12) 42 (4.29) 0.17 (0.28; 0.46) 0.40
NVT NVT total 215 (24.46) 417 (42.55) 1.29 (1.79; 0.88) <0.001
3 58 (6.60) 46 (4.69) 0.30(0.04; 0.53) 0.07
6C 4 (0.46) 18 (1.84) 3.09 (10.17; 0.50) 0.006
9A/N/L 9 (1.02) 13 (1.33) 0.30 (2.05; 0.45) 0.55
10 4 (0.46) 13 (1.33) 1.94 (7.60; 0.01) 0.05
11 42 (4.78) 42 (4.28) 0.11 (0.38; 0.42) 0.61
15 27 (3.07) 45 (4.60) 0.52 (1.46; 0.06) 0.09
16F 14 (1.59) 8 (0.82) 0.49 (0.20; 0.78) 0.12
21 5 (0.57) 32 (3.27) 4.90 (12.6; 1.56) <0.001
22 5 (0.57) 39 (3.98) 6.25 (15.2; 2.25) <0.001
23A 16 (1.82) 33 (3.37) 0.88 (2.41; 0.04) 0.04
23B 0 (0) 44 (4.49) Not calculated
33 5 (0.57) 10 (1.02) 0.80 (4.21; 0.38) 0.28
35B 3 (0.34) 26 (2.65) 6.96 (20.1; 1.89) <0.001
35F/47F 0 (0) 31 (3.16) Not calculated
38 12 (1.37) 5 (0.51) 0.63 (0.01; 0.87) 0.05
Other 11 (1.25) 12 (1.2) 0.02 (1.23; 0.57) 0.96
NT 38 (4.32) 33 (3.37) 0.23 (0.24; 0.52) 0.28
NONE 312 (35.50) 331 (33.78) 0.07 (0.12; 0.24) 0.44
Total 879 (100) 980 (100)
Indirect impact of the vaccination. PreVac period vs the PostVac period (study years: 2009–2011 vs 2013–2015). Only isolates from children born 2010 and earlier &
>3.5 years of age were included. k Conservative one-sided 95% confidence interval for vaccine impact. The total number is higher than the number of children due to some
children carrying more than one serotype.
Table 5
Vaccine impact of study 1 and study 2.
Study Impact on overall pneumococcal carriage (95% CI) Impact against vaccine types (95% CI) Impact against vaccine associated types (95% CI)
Overall 6A 19A
Study 1 1% (32; 22%) 94% (91; 96%) 33% (1; 55%) 33% (9; 59%) 29% (31; 61%)
Study 2 7% (12; 24%) 56% (44; 65%) 33% (8; 51%) 44% (12; 64%) 17% (28; 46%)
Impact on carriage prevalence in study 1 and in study 2. In study 1 Vaccine Eligible Children (birth-year 2011 and later) were compared to the Control Group (birth-year 2010
and earlier) and in study 2 older, Non-Vaccine-Eligible children (born 2010 and earlier) were compared before (calendar year: 2009–2011) and after the vaccination (calendar
year: 2013–2015).
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March every year when carriage may be higher during and shortly
after the frequent winter infections in this age group [8,38].
The total nasopharyngeal carriage remained high throughout
our study despite the reduction of VT. This can be attributed to ser-
otype replacement with NVTs. Serotype replacement has been
widely recognized after introduction of the pneumococcal vaccines
[9,12,21–26]. In the current study, non-vaccine serotypes/groups
most prevalent in the post vaccination years were 15, 11, 23B,
23A, 6C all with large increases in prevalence. This is similar to
other studies on PHiD-CV and PCV-13 [9,19,21,25,32], although
studies on PCV-13 generally show no difference or reduction in
the prevalence of 6C. This indicates that replacing serotypes in Ice-
land are similar to others using the higher valent vaccines.
For the VEC, a non-significant reduction was found for serotypes
6A and 19A, when considering each serotype individually, but with
a significant reduction in the combined prevalence. This is interest-
ing primarily due to the magnitude of serotype replacement wit-
nessed with other serotypes. Similar results were seen for the
PostVac period, which had significant herd effect on the carriage
of 6A but not 19A. Various studies have shown an increase in theprevalence of 19A after the implementation of the PCV-7 vaccine,
due to serotype replacement [15,21,23,24,32,39]. The PHiD-CV
direct effectiveness against 19A IPD has been reported in recent
years [2], with data suggesting similar direct effectiveness as the
PCV-13 vaccine [40]. Similar findings, albeit milder have been
reported for 6A IPD [13,19] and carriage of both 6A and 19A
[2,19], although other studies show less or no effectiveness against
acquisition [39,41,42]. This apparent discrepancy, where more
consistent data on 19A IPD effectiveness is available than for car-
riage, could be explained by the fact that the protection against
IPD is more complicated than can be explained by acquisition
alone [10].
This study shows replacement of serotypes non-susceptible to
penicillin, with the replacing serotypes exhibiting lower MIC. This
has been reported after the introduction of PCV-7 [23].
Pneumococcal isolates cultured from the VEC had less ery-
thromycin and co-trimoxazole resistance and were less often
multi-resistant as compared to CG. The reduction noted for the
VEC was mainly driven by the reduction in serotype 19F which
was the main PNSP and multi-resistant serotype in the pre-
vaccination period.
S. Sigurdsson et al. / Vaccine 35 (2017) 5242–5248 5247Due to a lack of herd effect on serotype 19F in the PostVac
cohort, as discussed above, no change in PNSP or multi resistance
was noted, but there was a reduction in co-trimoxazole resistance.
The resistant and multi-resistant NVTs, mainly of serogroup 15,
but also serotypes 6C and 23B, are emerging in the post vaccination
period. Reports on serogroup 15 have shown it to be one of the
most prevalent resistant serogroups in many parts of the world
[32,43]. Other studies have shown a decrease in non-susceptible
pneumococci after vaccination [9,22,44] or even no effect on
antibiotic resistance [45]. Many factors may influence this, the
most important being the level of antibiotic resistance in both
the vaccine serotypes and the replacing serotypes, the selective
pressure from antibiotic usage, the level of day-care attendance,
vaccine uptake in the study population in addition to study size
and design [5–9].
Different capsular types have varying invasive potential [10,46].
Replacing invasive [46], antibiotic resistant vaccine types with
more benign ones may result in a reduction in pneumococcal infec-
tions and treatment failures. Parent-reported antibiotic usage by
children in the VEC was lower than by children in the CG, yet with
no difference in RTIs. In the herd effect analysis, children in the
PostVac period had less antibiotic consumption and fewer recent
RTIs than those in the PreVac period. As this is parent-reported
and thus prone to recall bias, conclusions on vaccine impact on
RTI must be drawn with caution. The reduction noted here is how-
ever in line with other studies that show fewer infections after
PCVs [12–18,20].
The strength of this study is its size, its well-defined groups and
high vaccine uptake. All culturing and serotyping was done at the
same laboratory, using exactly the same methods and protocols
throughout the study period. The weakness is that it is a pre-
post analysis where the groups compared are sampled in different
years, and subject to different external factors, such as fluctuations
in serotype prevalence and incidence of viral infections that influ-
ence both pneumococcal carriage and disease. This cannot be
easily controlled in a study such as this and must be acknowledged
as a source of potential bias. However, the study periods compared
are directly adjacent to each other minimizing such differences.
Studies like this one, with monitoring of serotype prevalence,
serotype replacement and antibiotic resistance are important for
public health policies and treatment guidelines. Moreover, they
add to the important knowledge base needed for deciding which
serotypes should be included in the next generation of pneumo-
coccal vaccines. Importantly, it shows that the vaccination has
great impact against all VT in vaccinated children in addition to
herd effect on unvaccinated children contributing to lowering
antimicrobial resistance rates.
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